Light blue tube phlebotomy Market Foreseen to Grow With Key Companies Like Greiner BioOne, Medical Expo, CML Biotech., Ajosha BioTeklik

Various tests are performed using the light blue phlebotomy tube. Some of them are Partial Thromboplastin Time (PTT), Fibrin degradation products (FDP), Thrombin Time (TT), Prothrombin Time (PT), Fibrinogen, and D-dimer. The global light blue tube phlebotomy market is expected to swell at a considerable rate in the near future. Rise in health awareness has resulted in the increase in blood diagnostic tests; particularly coagulation tests owing to mounting incidences of low platelet count, increased prevalence of liver diseases, as well as growth in number of surgeries are factors that will be responsible for the growth of light blue tube phlebotomy market.

Light Blue Tube Phlebotomy Market Taxonomy

On the basis of type of end user the global light blue tube phlebotomy market is classified into:

Hospitals
Diagnostic Centers
Medical Clinics
Others

An important factor for using light blue top tubes is the amount of blood extracted in the tubes. The tubes should be filled to the brim for obtaining accurate results. The blood should continue to flow from the patient’s body into the tube until the tube is full and the blood flow ceases. If the blood is extracted through a syringe, the optimum level (as marked in most of the light blue top tubes) should be maintained. This factor is important because light blue top tubes are used for coagulation tests which require 9:1 blood to anticoagulant ratio.

Access PDF Template Copy of this Report at:
https://www.coherentmarketinsights.com/insight/request-pdf/143

Asia Pacific to be growth engine for global light blue tube phlebotomy market

Increasing incidence of blood related diseases is projected to create a highly conducive environment for growth of the global light blue tube phlebotomy market. According to Center for Disease Control and Prevention, almost 1 to 2 people could be affected by DVT/PE. Pulmonary embolism (PE) typically occurs when a blood clot known as a deep vein thrombosis (DVT), habitually in the leg, moves to the lungs and form a lump, thereby blocking a blood vessel. It results into to low oxygen levels in the blood. It can harm the lung and may cause heart failure as well. Therefore, a blood coagulation test is usually suggested to patients with a history of such diseases. In South Asia, particularly in India, the blood fibrinogen level is usually high, owing to high prevalence of CHD or coronary heart diseases and elevated levels of glycoprotein IIb/IIIa which work as a receiver for fibrinogen. Moreover, according to a report by Journal of Thrombosis and Hemostatis, there is a growing emphasis upon the requirement of a controlled and randomized evaluation with clinical result measurement to ascertain that thromboprophylaxis (avoidance of thromboembolic disease or impediment of blood vessels by blood clot) is crucial in joint surgery in Asia. As blood coagulation tests are generally recommended before and after a surgery, escalation in the number of surgeries around the world is expected fuel the light blue tube phlebotomy market during the forecast period.

Key players in the global light blue tube phlebotomy market

Some of the major competitors operating in the global light blue tube phlebotomy market are Greiner BioOne, Medical Expo, CML Biotech Pvt. Ltd., Ajosha BioTeklik Pvt. Ltd., New MicroMed International Pvt. Ltd., FL Medical, Gosselin, and Advacare Pharma.

Get Customized Report in your Inbox within 24 hours @
https://www.coherentmarketinsights.com/insight/request-customization/143

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.